Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:6903 |
| Name | eye lymphoma |
| Definition | A lymphoma by site that is manifested in immune system cells called lymphocytes. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer sensory system cancer ocular cancer eye lymphoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03964090 | Phase II | Cytarabine + Dexamethasone + Etoposide + Isavuconazole + Pegylated liposomal doxorubicin + Rituximab + Temozolomide Cytarabine + Dexamethasone + Etoposide + Ibrutinib + Isavuconazole + Pegylated liposomal doxorubicin + Rituximab + Temozolomide | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | Active, not recruiting | USA | 0 |